Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11034505 | 1.00 | TYR (0.42) | TYRTHRBLMNATACR1CA12 | |
| SCHEMBL13096293 | 0.95 | TYR (0.46) | TYRTHRBLMNATACR1CA12 | |
| SCHEMBL26385620 | 0.95 | TYR (0.46) | TYRTHRBLMNATACR1CA12 | |
| SCHEMBL18622063 | 0.95 | TYR (0.46) | TYRTHRBLMNATACR1CA12 | |
| SCHEMBL6932467 | 0.83 | TYR (0.32) | TYR | |
| SCHEMBL25976247 | 0.78 | TYR (0.35) | TYR | |
| SCHEMBL26443544 | 0.78 | TYR (0.35) | TYR | |
| SCHEMBL6933634 | 0.78 | TYR (0.30) | TYR | |
| SCHEMBL11082587 | 0.78 | TYR (0.50) | TYRTHRBTACR1CA12CA9 | |
| SCHEMBL3246578 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134986-A1 | GLUCOSE TRIPTOLIDE CONJUGATES AND USES THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230134986-A1 | GLUCOSE TRIPTOLIDE CONJUGATES AND USES THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2010096650-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | TYR 2226/4885THRB 1816/4885LMNA 4561/4885 |
| US-20230134986-A1 | GLUCOSE TRIPTOLIDE CONJUGATES AND USES THEREOF | SLC2A1, SLC2A9, GID4 | TYR 2531/4885THRB 1349/4885LMNA 4637/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | TYR 2108/4885THRB 2043/4885LMNA 4410/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | TYR 4510/4885THRB 2984/4885LMNA 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.